Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Acquired R&D Technology Rights by Quarter
Acquired R&D Technology Rights — Gross Carrying Value ($M) ($M)
Amgen Acquired R&D Technology Rights: $1,409M in Q2 2026, down 0.7% from a year earlier.
Latest, Q2 2026
1,409
Period ended Jun 30, 2026
Change on a year earlier
-0.7%
1,419 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired R&D Technology Rights — Gross Carrying Value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,409 | -0.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,416 | +2.1% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,425 | +3.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,421 | +1.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,419 | +2.6% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,387 | -0.1% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,374 | -1.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,400 | +1.7% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,383 | -0.6% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,388 | +0.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,394 | +1.2% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,377 | +3.2% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,392 | +1.5% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,387 | +0.1% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,378 | +0.1% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,334 | +2.8% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,371 | +4.8% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,386 | +6.5% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,377 | +4.6% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,298 | +0.2% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,308 | +2.3% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,301 | +2.5% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,317 | +3.5% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,295 | +2.3% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,279 | +11.4% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,269 | +10.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,273 | +10.9% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,266 | +9.2% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,148 | -0.6% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,145 | -2.7% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,148 | -1.1% | Form 10-Q (filed 2019-10-30) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,159 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,155 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,177 | – | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,161 | +3.5% | Form 10-K (filed 2019-02-13) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,122 | -1.1% | Form 10-K (filed 2018-02-13) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,134 | – | Form 10-K (filed 2017-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Acquired R&D Technology Rights ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl-rdtech-gross
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.